Pfizer ships out two cancer ADCs alongside its tech platform to Pyxis Oncology, and its familiar CEO
The hype around antibody-drug conjugates (ADCs) has been growing in recent years after big bucks deals and approvals from the likes of AstraZeneca/Daiichi and Immunomedics putting a spotlight on the approach.